Bruker AXS Files Registration for Initial Public Offering
Bruker AXS has filed a registration statement with the US Securities and Exchange Commission for an initial public offering of its common stock.
Despite seemingly adverse economic conditions, the Madison, Wis.-based supplier of x-ray crystallography, x-ray diffraction, and x-ray fluorescence systems stated in its filing that it plans to sell 9 million shares at an estimated price of $8 to $10 per share, with an over-allotment of 1.35 million shares.
Bruker AXS’ sister company, mass spectrometry manufacturer Bruker Daltonics, completed its IPO in August of last year, raising $104 million.
Polaroid Releases High-Res Camera for Gel Imaging
Cambridge, Mass.-based Polaroid has launched a new high-resolution digital camera for imaging gels used in DNA and protein separations, the company announced earlier this month.
The camera, called a GelCam, includes a variable-sized hood and image analysis software. The product sells for $1,799.
Pfizer Joins Accelrys’ HTP Crystallography Group
Pfizer has joined Accelrys’ High Throughput Crystallography Consortium, Accelrys announced last week.
Princeton, NJ-based Accelrys, a subsidiary of Pharmacopeia, created the consortium to explore and validate rapid methods for x-ray structure determination, model building, and structure validation, according to the company. The agreement with Pfizer covers a number of sites, including Sandwich, UK, Groton, Conn., Ann Arbor, Mich., and La Jolla, Calif.
With Pfizer, the consortium’s total membership is 13 companies, including Bristol-Myers Squibb, Genencor, and the Genetics Institute.
GeneFormatics Names CEO of Sangamo to Board
Sangamo Biosciences founder and CEO Edward Lanphier has joined GeneFormatics’ board of directors, GeneFormatics said last week.
Prior to founding Sangamo Biosciences, Lanphier served as a senior executive at Somatix Therapy, and as vice president for business development at Synergen and Eli Lilly. He also held the position of president and CEO of BioGrowth.
ProteEx Scores Five Fee-for-Service Contracts with UT
Startup proteomics research company ProteEx has contracted with the University of Texas Health Science Center and MD Anderson Cancer Center to perform five proteomics studies for academic researchers, the company said last week.
Located in The Woodlands, Texas, the year and a half-old company will perform contract research for the University of Texas Health Science Center in the areas of tumor suppressor proteins in nuclear regulation of colon cancer, phosphoproteins involved in immuno-suppressive disorders, and nitrosylated proteins involved in renal and cardiovascular disease.
ProteEx also has contracts with several undisclosed pharma companies, the company said.